Aerosols as drug carriers

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 367-395

  Labiris, N Renée ^a   Bosco, Andrew P ^a   Dolovich, Myrna B ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER;

DRUG DELIVERY;

EID: 84967367178     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0017     Document Type: Chapter

References (105)

1. Horsfield K, Dart G, Olson DE, Filley GF and Cumming G (1971) Models of the human bronchial tree. J Appl Physiol 31:207-217.
2. Kreuter J (1994) Drug targeting with nanoparticles. Eur J Drug Met Pharmacol 19:253-256.
3. Ghirardelli R, Bonasoro F, Porta C and Cremaschi D (1999) Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit. Biochim Biophys Acta 12:1-2.
4. Huang M, Ma Z, Khor E and Lim LY (2002) Uptake of FITC-chitosan nanoparticles in A549 cells. Pharm Res 19:1488-1494.
5. Russell-Jones GJ, Veitch H and Arthur L (1999) Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int J Pharm 190:165-174.
6. Brigger I, Dubernet C and Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 54:631-651.
7. Martonen TB (1993) Mathematical model for the selective deposition of inhaled pharmaceuticals. J Pharm Sci 82:1191-1199.
8. O’Callaghan C and Barry PW (1997) The science of nebulized drug delivery. Thorax 52 (Suppl 2):s31-s44.
9. Denyer J, Dyche T, Nikander K, Newman SP, Richards J and Dean A (1997) Halolite a novel liquid drug aerosol delivery system. Thorax 52(suppl 6):208.
10. Dolovich M (1999) New propellant-free technologies under investigation. J Aerosol Med 12(Suppl 1):s9-s17.
11. Smaldone GC, Agosti J, Castillo R, Cipolla D and Blanchard JD (1999) Deposition of radiolabelled protein from AERx in patients with asthma. J Aerosol Med 12:98.
12. Newman SP and Clarke SW (1992) Inhalation devices and techniques, in Clark TJH, Godfrey S and Lee TH (eds.), Asthma. Chapman & Hall, London, pp. 469-455.
13. Newman SP, Pavia D, Moren F, Sheahan NF and Clarke SW (1981) Deposition of pressurized aerosols in the human respiratory tract. Thorax 36:52-55.
14. Crompton GK (1982) Problems patients have using pressurized aerosol inhalers. European Journal of Respiratory Diseases - Supplement 119:101-104.
15. Bennett WD and Smaldone GC (1987) Human ventilation in the peripheral air-space deposition of inhaled particles. Am J Physiol 62:1603-1610.
16. Dolovich M, Ryan G and Newhouse MT (1981) Aerosol penetration into the lung. Influence on airway responses. Chest 80 (suppl)(6):834-836.
17. Newman SP, Pavia D, Garland N and Clarke SW (1982) Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis 63 (Suppl. 119):57-65.
18. Pavia D, Thomson ML, Clarke SW and Shannon HS (1977) Effects of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax 32:194-197.
19. Dolovich M, Ruffin RE, Roberts R and Newhouse MT (1981) Optimal delivery of aerosols from metered dose inhalers. Chest 80:911-915.
20. Dolovich MB (1995) Characterization of medical aerosols: Physical and clinical requirements for new inhalers. Aerosol Sci Technol 22:392-399.
21. Dolovich M, Chambers C, Mazza M and Newhouse MT (1992) Relative efficiency of four metered dose inhaler (MDI) holding chambers (HC) compared to albuterol MDI. J Aerosol Med 5:307.
22. Dolovich M, Ruffin R, Corr D and Newhouse MT (1983) Clinical evaluation of the Aerochamber: A simple demand inhalation MDI delivery device. Chest 84:36-41.
23. Newman SP, Moren F, Trofast E, Talaee N and Clarke SW (1989) Deposition and clinical efficacy of terbutaline sulphate from Turbohaler, a new multi-dose inhaler. Eur Respir J 2:247-252.
24. Pedersen S (1996) Inhalers and nebulizers: Which to choose and why. Respiratory Medicine 90:69-77.
25. Newhouse MT and Kennedy A (2000) Condensation due to rapid, large temperature (t) changes impairs aerosol dispersion from Turbuhaler(T). Am J Respir Cell Mol Biol 161(3):A35.
26. Newhouse MT and Kennedy A (2000) Inspiryl Turbuhaler (ITH) DPI vs. Ventolin MDI + Aerochamber (AC): Aerosol dispersion at high and low flow and relative humidity/temperature (RH/T) in vitro. Am J Respir Crit Care Med 161(3):A35.
27. Borgstrom L, Bondesson E, Moren F, Trofast E and Newman SP (1994) Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects. Euro Respir J 7:(1) 69-73.
28. Richards R and Saunders M (1993) Need for a comparative performance standard for dry powder inhalers. Thorax 48:1186-1187.
29. Everard ML, Devadason SG and Le Souef PN (1997) Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 91:624-628.
30. Newman SP, Hollingworth Aand Clark AR (1994) Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharma 102:127-132.
31. Newman SP, Moren F, Trofast E, Talaee N and Clarke SW (1991) Terbutaline sulphate Turbuhaler: Effect of inhaled flow rate on drug deposition and efficacy. Int J Pharma 74:209-213.
32. Clark AR and Hollingworth AM (1993) The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - Implications for in vitro testing. J Aerosol Med 6(2):99-110.
33. Svartengren K, Lindestad PA, Svartengren M, Philipson K, Bilin G and Camner P (1995) Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 152:32-37.
34. Melchor R, Biddiscombe MF, Mak VH, Short MD and Spiro SG (1993) Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48(5):506-511.
35. Vidgren M, Paronen P, Vidgren P, Vainio P and Nuutinen J (1990) In vivo evaluation of the new multiple dose powder inhaler and the Rotahaler using the gamma scintigraphy. Acta Pharma Nordica 2(1):3-10.
36. Borgstrom L and Newman SP (1993) Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler. Int J Pharma 97:47-53.
37. Ruffin RE, Dolovich MB, Wolff RK and Newhouse MT (1978) The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis 117(3):485-492.
38. Lourenco RV and Cotromanes E (1982) Clinical aerosols. I. Characterization of aerosols and their diagnositic uses. Arch Intern Med 142:2163-2172.
39. Heyder J. (1982) Particle transport onto human airway surfaces. Eur J Respir Dis 63(Suppl 119):29-50.
40. Brain JD and Blanchard JD (1993) Mechanisms aerosol deposition and clearance, in Moren F, Newhouse MT and Dolovich MB (eds.), Aerosols in Medicine. Principles, Diagnosis and Therapy. Elsevier Science Publishers, New York, pp. 117-156.
41. Gerrity TR (1990) Pathophysiological and disease constraints on aerosol deposition, in Byron PR (ed.), Respiratory Drug Delivery. Boca Raton, CRC Press, Inc., Florida, 1990: 1-38.
42. Effros RM and Mason GR (1983) Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 127(suppl):s59-s66.
43. Folkesson HG, Westrom BR and Karlsson BW (1990) Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand 139:347-354.
44. Patton JS (1996) Mechanisms of macromolecule absorption by the lungs. Adv Drug Del Rev 19:3-36.
45. Carstairs JR, Nimmo AJ and Barnes PJ (1985) Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 132:541-547.
46. Mak JCW and Barnes PJ (1990) Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 141:1559-1568.
47. Rees PJ, Clark TJ and Moren F (1982) The importance of particle size in response to inhaled bronchodilators. European Journal of Respiratory Diseases - Supplement 119:73-78.
48. Zanen P, Go LT and Lammers J-WJ (1994) The optimal particle size for β-adrenergic aerosols in mild asthmatics. Int J Pharma 107:211-217.
49. 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51:977-980.
50. Baskin ML, Abd AG and Ilowite JS (1990) Regional deposition of aerosolized pentamidine. Effects of body position and breathing pattern. Ann Int Med 113:677-683.
51. Gerrity TR, Garrard CS and Yeates DB (1981) Theoretical analysis of sites of aerosol deposition in the human lung. Chest 80(suppl 6):898-901.
52. Baltimore RS, Christie CDC and Walker Smith GJ (1989) Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis 140:1650-1661.
53. Potts SB, Roggli VL and Spock A (1995) Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatric Pathol Lab Med 15:707-721.
54. Alderson PO, Secker-Walker RH, Stominger DB et al. (1974) Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr 84:479-484.
55. Ilowite JS, Gorvoy JD and Smaldone GC (1987) Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 136:1445-1449.
56. Anderson PJ, Blanchard JD, Brain JD, Feldman HA, McNamara JJ and Heyder J (1989) Effect of cystic fibrosis on inhaled aerosol boluses. Am Rev Respir Dis 140:1317-1324.
57. Wolff RK (1998) Safety of inhaled proteins for therapeutic use. J Aerosol Med 11(4):197-219.
58. Farr ST, Gonda I and Licko V (1998) Physicochemical and physiological factors influencing the effectiveness of inhaled insulin, in Dalby RN, Byron PR and Farr ST (eds.), in Respiratory Drug Delivery VI, Interpharm Press Inc., Buffalo Grove, IL, pp. 25-33.
59. Laube BL, Georgopoulos A and Adams GKI (1993) Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 269(16): 2106-2109.
60. Jendle JH and Karlberg BE (1996) Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 56:555-561.
61. Jendle JH and Karlberg BE (1996) Intrapulmonary administration of insulin to healthy volunteers. J Int Med 240:93-98.
62. Laube BL, Benedict GW and Dobs AS (1998) Time to peak insulin level, relative bioavailability, and effect of size of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. J Aerosol Med 11(3):153-173.
63. Byron PR and Patton JS (1994) Drug delivery via the respiratory tract. J Aerosol Med 7(1):49-75.
64. Ma JKH, Bhat M and Rojanasakul Y (1996) Drug metabolism and enzyme kinetics in the lung, in: Lenfant C (ed.), Inhalation Aerosols. Physical and Biological Basis for Therapy. Marcel Dekker: New York, NY, 94:155-195.
65. Folkesson HG, Matthey MA, Westrom BR, Kim KJ, Karlsson BW and Hastings RH (1996) Alveolar epithelial clearance of protein. J Appl Physiol 80(5): 1431-1445.
66. Newman SP (1985) Aerosol deposition considerations in inhalation therapy. Chest 88(suppl): 152s-160s.
67. Phipps PR, Gonda I, Anderson SD, Bailey D and Bautovich G (1994) Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Euro Respir J 7(8):1474-1482.
68. Swift DL (1980) Aerosols and humidity therapy: Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis 122:71-91.
69. Ferron GA, Oberdörster G and Henneberg R (1989) Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth. J Aerosol Med 2(3):271-284.
70. Xu GB and Yu CP. (1985) Theoretical lung deposition of hygroscopic NaCl aerosols. Aerosol Sci Technol 4:455-461.
71. Smaldone GC, Perry RJ, Bennett WD, Messina MS, Zwang J and Ilowite J (1988) Interpretation of “24 hour lung retention” in Studies of Mucociliary Clearance. J Aerosol Med 1:11-20.
72. Houtmeyers E, Gosselink R, Gayan-Ramirez G and Decramer M (1999) Regulation of mucociliary clearance in health and disease. Eur Respir J 13:1177-1188.
73. Rossman CM, Lee RMKW, Forrest JB and Newhouse MT (1984) Nasal ciliary ultrastructure and function in patients with primary ciliary dyskinesia compared with that in normal subjects and in subjects with various respiratory diseases. Am Rev Respir Dis 129(1):161-167.
74. Rossman CM, Waldes OR, Sampson D and Newhouse MT (1982) Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. Am Rev Respir Dis 126:131-135.
75. Robinson M (2002) Bye PTB. Mucociliary clearance in cystic fibrosis. Pediatric Pulmonol 33:293-306.
76. Isawa T, Teshima T, Hirano T, Anazawa Y, Miki M, Konno K and Motomiya M (1990) Mucociliary clearance and transport in bronchiectasis: Global and regional assessment. J Nucl Med 31:543-548.
77. Edsbacker S (2002) Uptake, retention and biotransformation of corticosteroids in the lung and airways, in Schleimer RP, O’Byrne PM, Szefler SJ and Brattsand R (eds.), Inhaled Steroids in Asthma: Optimizing Effects in the Airways, Marcel Dekker, Inc., New York, pp. 213-246.
78. Summers QA. (1991) Inhaled drugs and the lung. Clin Exp Allergy 21:259268.
79. Stone KC, Mercer RR, Gehr P, Stockstill B and Crapo JD (1992) Allometric relationship of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 6:235-243.
80. Conhaim RL, Eaton A, Staub NC and Heath TD (1988) Equivalent pore estimate for the alveolar-airway barrier in isolated dog lung. J Appl Physiol 64:1134-1142.
81. Barrowcliffe MPA, Jones JG and Sever PS (1986) Pulmonary clearance of vasoactive intestinal peptide. Thorax 41:88-93.
82. Nemmar A, Hoet PHM, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, Vanbilloen H, Mortelmans L and Nemery B (2002) Passage of inhaled particles into the blood circulation in humans. Circulation 105:411-414.
83. Sham JO-H, Zhang Y, Finlay WH, Roa WH and Lobenberg R (2004) Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharma 269:457-467.
84. Leach CL, Davidson PJ and Boudreau RJ (1998) Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur Respir J 12:1346-1353.
85. Dickinson PA, Howells SW and Kellaway IW (2001) Novel nanoparticles for pulmonary drug administration. J Drug Targ 9(4):295-302.
86. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE and Waldman SA (2004) The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharma 44(1):67-72.
87. Kramer EL and Divgi CR (1991) Pulmonary applications of nuclear medicine. Clin Chest Med 12(1):55-75.
88. 133Xe dynamic SPECT in pulmonary emphysema. Ann Nuclear Med 11:201-206.
89. Isawa T, Teshima T, Anazawa Y, Miki M and Motomiya M (1991) Technegas for inhalation lung imaging. Nucl Med Commun 12:47-55.
90. Videira MA, Botelho MF, Santos AC, Gouveia LF, Pedrosos De Lima JJ and Almeida AJ (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Targ 10(8):607-613.
91. Mclntire GL, Bacon ER, Toner JL, Cornacoff JB, Losco PE, Illig KJ, Nikula KJ, Muggenburg BA and Ketai L (1998) Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. J Pharma Sci 87(11):1466-1470.
92. Lamm ME (1997) Interactions of antigens and antibodies at mucosal surfaces. Ann Rev Microbiol 51:311-340.
93. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila Jato J and Alonso MJ (2004) Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharmaceut Biopharmeut 57:123-131.
94. Vila A, Sanchez A, Evora C, Soriano I, Vila Jato J and Alonso MJ (2004) PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17(2):174-185.
95. Tobio M, Gref R, Sanchez A, Langer R and Alonso MJ (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharma Res 15(2): 270-275.
96. Jung T, Kamm W, Breitenbach A, Hungerer K-D, Hundt E and Kissel T (2001) Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graftpoly(lactide-co-glycolide): Evaluation of antibody response after oral and nasal application in mice. Pharma Res 18(3):352-360.
97. Pinto-Alphandary H, Andremont A and Couvreur P (2000) Trgeted delivery of antibiotics using liposomes and nanoparticles: Research and applications. Int J Antimicrobial Agents 13(3):155-168.
98. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK and Prasad B (2003) Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52(6):981-986.
99. Sharma A, Sharma S and Khuller GK (2004) Lectin-functionalized poly (lactide-coglycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 54(4):761-766.
100. Yoshida M, Leigh R, Matsumoto K, Wattie J, Ellis R and O’Byrne PM (2002) Effect of interferon-gamma on allergic airway responses in interferon-gamma-deficient mice. Am J Respir Crit Care Med 166:451-456.
101. Kumar M, Kong X, Behera AK, Hellermann GR, Lockey RF and Mohapatra SS (2003) Chitosan IFN-y-pDNA nanoparticle (CIN) therapy for allergic asthma. Gen Vacc Ther 1:3-11.
102. Bivas-Benita M, Romeijn S, Junginger HE and Borchard G (2004) PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharmaceut Biopharmeut 58:1-6.
103. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ and Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2):179-186.
104. Zhang W, Yang H, Kong X, Mohapatra S, Juan-Vergara HS, Hellermann G, Behera S, Singam R, Lockey RF and Mohapatra SS (2005) Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 11(1):56-62.
105. Dolovich MB and Newhouse MT. (1993) Aerosols. Generation, methods of administration, and therapeutic applications in asthma, in Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW and Busse WW (eds.), Allergy. Principles and Practice, Mosby - Year Book, Inc., St. Louis, 712-739.